0RAD Stock Overview A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
OSE Immunotherapeutics SA Competitors Price History & Performance
Summary of share price highs, lows and changes for OSE Immunotherapeutics Historical stock prices Current Share Price €6.94 52 Week High €11.22 52 Week Low €3.25 Beta 0.83 1 Month Change -20.32% 3 Month Change -9.16% 1 Year Change 69.68% 3 Year Change -35.15% 5 Year Change n/a Change since IPO 15.67%
Recent News & Updates
Investor sentiment deteriorates as stock falls 16% Dec 20
Investor sentiment deteriorates as stock falls 19% Dec 04
Investor sentiment improves as stock rises 18% Oct 22
First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023) Sep 29
New major risk - Revenue and earnings growth Sep 27
New major risk - Revenue and earnings growth Jul 02 See more updates
Investor sentiment deteriorates as stock falls 16% Dec 20
Investor sentiment deteriorates as stock falls 19% Dec 04
Investor sentiment improves as stock rises 18% Oct 22
First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023) Sep 29
New major risk - Revenue and earnings growth Sep 27
New major risk - Revenue and earnings growth Jul 02
OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco Jun 20
Forecast breakeven date moved forward to 2024 Jun 06
OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024 May 09
Full year 2023 earnings released: €1.18 loss per share (vs €0.96 loss in FY 2022) Mar 31
OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors Feb 27
New minor risk - Share price stability Feb 24
New minor risk - Shareholder dilution Jan 25
OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant Dec 11
Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody Oct 24
First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022) Sep 29
Forecast breakeven date moved forward to 2024 Sep 28
New major risk - Financial position Sep 28
High number of new directors Aug 05
OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation Jul 22
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation Jul 12 OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist
High number of new directors Jul 05 OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director
OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting Jun 06
OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023 Jun 01
OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer May 25
Forecast to breakeven in 2025 May 23
Full year 2022 earnings released: €0.96 loss per share (vs €0.93 loss in FY 2021) Apr 29
OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies Feb 16
OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas Dec 22
OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting Dec 12
Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1 Nov 23
Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome Nov 03
OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies Oct 21
OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer Oct 08
First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021) Sep 24
Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022 Sep 07
Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022 Sep 06
OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer Jul 14
OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022 Jun 24 OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology May 04
OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy May 03
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy Apr 06
No longer forecast to breakeven Apr 01
OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022 Mar 31
Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors Mar 10
OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors Feb 19
OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104 Feb 01
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients Jan 26 OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis
OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine Nov 30
First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020) Sep 23
OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021 Sep 13
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer Aug 27
Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome Aug 26
OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study Jul 20
Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer May 28
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine May 26
OSE Immunotherapeutics SA and Boehringer Ingelheim to Present Positive Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Asco 2021 May 21
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE). Apr 27
OSE Immunotherapeutics Sa and ARCAGY - GINECO Announces Initiation of A Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer Mar 15
OSE Immunotherapeutics SA to Present New Data Reflecting Expansion and Progress on Its Immuno-Oncology and Inflammation Preclinical Portfolio At the 2021 Aacr Annual Meeting Mar 13
OSE Immunotherapeutics SA Announces Granting of First European Patent Protecting Anti-Il-7 Receptor Antagonist OSE-127/S95011 Feb 18
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics Jan 29
OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011 Jan 26
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 Dec 23
OSE Immunotherapeutics Receives €5.2 Million in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine Dec 19
OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation Dec 04
OSE Immunotherapeutics Provides COVID-19 Vaccine Update on Covepit Nov 07
OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104 Oct 13
OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi in NSCLC at the European Society for Medical Oncology Virtual Congress 2020 Sep 22
First half earnings released Sep 20 Shareholder Returns 0RAD GB Biotechs GB Market 7D -10.1% -5.1% -2.2% 1Y 69.7% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0RAD exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0RAD exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0RAD's price volatile compared to industry and market? 0RAD volatility 0RAD Average Weekly Movement 10.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0RAD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RAD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
Show more OSE Immunotherapeutics SA Fundamentals Summary How do OSE Immunotherapeutics's earnings and revenue compare to its market cap? 0RAD fundamental statistics Market cap €153.58m Earnings (TTM ) €46.03m Revenue (TTM ) €83.44m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RAD income statement (TTM ) Revenue €83.44m Cost of Revenue €0 Gross Profit €83.44m Other Expenses €37.41m Earnings €46.03m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 2.12 Gross Margin 100.00% Net Profit Margin 55.17% Debt/Equity Ratio 49.6%
How did 0RAD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 11:49 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OSE Immunotherapeutics SA is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Olga Smolentseva Bryan Garnier & Co David Seynnaeve Degroof Petercam Laura Roba Degroof Petercam
Show 5 more analysts 
